NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

Phase 2

Active, not recruiting

Conditions: Erythroplakia
Oral Cavity Carcinoma
Oral Leukoplakia
Hyperplasia

Interventions: Other: Laboratory Biomarker Analysis
Drug: Metformin Hydrochloride

First Posted Date: 2015-10-20

Last Posted Date: 2025-01-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT02581137

Locations: 🇺🇸
UC San Diego Medical Center - Hillcrest, San Diego, California, United States
🇨🇦
BC Cancer Research Centre, Vancouver, British Columbia, Canada
🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 1 locations

Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)

Phase 2

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: 67.5 mg oral insulin crystals daily
Drug: 500mg oral insulin crystals every other week

First Posted Date: 2015-10-20

Last Posted Date: 2020-07-27

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 92

Registration Number: NCT02580877

Locations: 🇺🇸
Emory Children's Center, Atlanta, Georgia, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 16 locations

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Phase 2

Terminated

Conditions: Refractory Anaplastic Large Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Refractory Mantle Cell Lymphoma
Refractory Transformed Non-Hodgkin Lymphoma
Recurrent Anaplastic Large Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Drug: Onalespib

First Posted Date: 2015-10-09

Last Posted Date: 2022-09-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT02572453

Locations: 🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 16 locations

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

Phase 2

Active, not recruiting

Conditions: Human Papillomavirus-Related Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Recombinant Human Papillomavirus Nonavalent Vaccine

First Posted Date: 2015-10-06

Last Posted Date: 2025-02-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 201

Registration Number: NCT02568566

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent Burkitt Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Grade 3a Follicular Lymphoma
Recurrent Grade 3b Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Gray-Zone Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma

Interventions: Biological: Blinatumomab
Drug: Lenalidomide

First Posted Date: 2015-10-06

Last Posted Date: 2025-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT02568553

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 21 locations

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Phase 1

Active, not recruiting

Conditions: Head and Neck Carcinoma of Unknown Primary
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Head and Neck Squamous Cell Carcinoma
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7
Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7
Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

Interventions: Drug: Berzosertib
Drug: Cisplatin
Procedure: Computed Tomography
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy

First Posted Date: 2015-10-05

Last Posted Date: 2024-05-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT02567422

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

and more 16 locations

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1

Withdrawn

Conditions: Head and Neck Squamous Cell Carcinoma
Stage III Mesothelioma
Stage IIIC Ovarian Cancer
Stage IV Ovarian Cancer
Metastatic Pancreatic Adenocarcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer
Triple-Negative Breast Carcinoma
Stage IIIA Ovarian Cancer
Stage IIIA Small Cell Lung Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Talazoparib

First Posted Date: 2015-10-05

Last Posted Date: 2017-04-24

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02567396

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Phase 2

Completed

Conditions: Stage IV Bladder Urothelial Carcinoma AJCC v7
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma

Interventions: Drug: Berzosertib
Drug: Cisplatin
Drug: Gemcitabine Hydrochloride

First Posted Date: 2015-10-05

Last Posted Date: 2025-03-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 87

Registration Number: NCT02567409

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 36 locations

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Phase 3

Active, not recruiting

Conditions: Alveolar Rhabdomyosarcoma
Botryoid-Type Embryonal Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma
Sclerosing Rhabdomyosarcoma
Rhabdomyosarcoma
Spindle Cell Rhabdomyosarcoma

Interventions: Drug: Cyclophosphamide
Biological: Dactinomycin
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration
Radiation: Radiation Therapy
Drug: Vincristine Sulfate
Drug: Temsirolimus
Drug: Vinorelbine

First Posted Date: 2015-10-05

Last Posted Date: 2025-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 325

Registration Number: NCT02567435

Locations: 🇺🇸
Saint Mary's Medical Center, West Palm Beach, Florida, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States

and more 383 locations

Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)

Terminated

Conditions: Genetics

First Posted Date: 2015-10-02

Last Posted Date: 2021-03-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 957

Registration Number: NCT02566161

Locations: 🇺🇦
Research Center for Radiation Medicine, Kiev, Ukraine

Home Terms & Conditions Privacy Policy